Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
about
Adjuvant medical treatment for breast cancer in elderly and old womenSurveillance and Care of the Gynecologic Cancer SurvivorOsteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.Imaging biomarker roadmap for cancer studiesAromatase inhibitors-induced bone loss in early breast cancer.Cancer screening and preventative care among long-term cancer survivors in the United Kingdom.The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial.Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: validation of the WHO FRAX ™ tool in Spain.Does adjuvant chemotherapy change bone mineral density and related serum biomarkers in women with breast cancer?Increased fracture rate in women with breast cancer: a review of the hidden risk.Caring for the breast cancer survivor's health and well-being.A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer.Management options of breast cancer related osteoporosis.Medication-induced osteoporosis: screening and treatment strategiesZoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.Bone health history in breast cancer patients on aromatase inhibitors.Intervening on the side effects of hormone-dependent cancer treatment: the role of strength training.Prevention of bone metastases and management of bone health in early breast cancer.Osteoporosis after breast cancer chemotherapy: a case report.Follow-up care for cancer survivors: the views of clinicians.Fragility fracture: recent developments in risk assessment.Breast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer.Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?The treatment of early breast cancer in women over the age of 70Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for managementOptimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.Cancer Treatment-Induced Bone Loss in women with breast cancerDiagnosis and treatment of early breast cancer, including locally advanced disease--summary of NICE guidance.Long-term health consequences of premature or early menopause and considerations for managementTibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy.The management of osteoporosis in breast cancer survivors.Are patients with newly diagnosed breast cancer getting appropriate DEXA scans? A District General Hospital experience.Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trialPrevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN TrialEffects of anastrozole combined with Shuganjiangu decoction on osteoblast-like cell proliferation, differentiation and OPG/RANKL mRNA expression.Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors.Long-term efficacy and safety of exemestane in the treatment of breast cancerItalian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women.Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy.
P2860
Q26749063-3C54B940-07E5-4A24-B3D1-74800DE475B9Q26799810-EDA339EC-A1AD-4E3C-A8AA-F760A167FA09Q30235173-2BE83E8C-1691-4E83-8F39-443CEE510C4FQ30242020-A9C8E65D-0F0A-44F9-8E9C-03F90E9E81B7Q33752867-B60EFCD2-5A80-4FB1-A073-EB3268BECC14Q33783086-3E85B836-2511-4ED1-A62A-7DBA80ED0ABDQ33802932-740C8FF1-F0F3-4D5A-9350-C25C9FACC559Q33805608-37842B94-2181-4CFA-A84D-6E5BD72D8D7DQ33862200-A0FF7018-027C-4EF5-B495-1B39710217CDQ34004925-F16CFE6F-8AAB-4C58-B7EE-ADD8177BFD87Q34031251-D7EE42FD-D9EC-4A75-81A3-D0FDB814CE73Q34199333-5E559879-B721-4186-A4E2-5A0EEF783DBDQ34230292-EC3BFDC2-548D-4A65-BC34-FAB7DA6AD754Q34389358-FAB892E0-26C7-4883-A537-1E14AD8D644AQ34414177-2D3B981E-8257-41A4-B3C4-6FF13B8E9CECQ34421028-62438829-B015-4A1D-89CE-0054448B419FQ34557490-6E272646-F2C7-477C-84FD-F922E346FDECQ34613485-0ECACFC9-E4CB-4FCF-8EF5-03DC1C25DBECQ34986340-C0C6BF8C-38C2-44AF-BDD1-6EDB00E6D42AQ34994605-884980C6-DB70-4CFF-8247-A6D002EE4E4BQ35039567-C847FCED-FA92-4624-B227-8F1F881E68FEQ35066907-140FB3F9-6100-48AB-B1A8-B53F62BCA57EQ35076216-FDAAB3FD-8AC3-4A2E-AC31-61B44A1308FAQ35125666-CD9A775A-EAF8-46D3-8270-6A723ED47123Q35558893-3E75619D-8E18-4421-85BC-A5FBF15C4007Q35583788-E9BB935B-811C-4EBA-AEF8-1A1F605005A4Q35632616-BB89F866-8A25-4547-8A51-1D256280E492Q35699320-1E5CC162-B50B-4ACF-B8E1-93679AA8AFDAQ36089352-257E8025-AD32-4998-A05A-2F64F2EB46EEQ36393138-6B5F5B21-C478-41BC-9047-59C070498E7CQ36405775-B8B55CD4-0AF6-4429-B15C-C2087D82298EQ36409294-0D1C55FB-459B-46A9-B00A-C673E13F18F5Q36491348-A8FE37E6-B4CD-4F58-9967-859D8A2E3004Q36491519-E02BB5A0-99C5-4BAA-B8EB-1C9355307202Q36563142-FFDB6D4B-4F5B-4B5B-BDDC-351911AC8DBCQ36613577-6570A974-6BF1-48C0-8DFD-00637530C5EAQ36739182-1E80E645-DC74-47B5-93D0-B5140F5B90FAQ37135281-B48F5B71-B3A2-4AFB-B325-544C934BEF02Q37213718-778295FB-EDB5-41FB-8D25-65AC640DC225Q37350988-098E0307-094D-4F1E-B1AB-B3322BA7F1FD
P2860
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Guidance for the management of ...... tement from a UK Expert Group.
@en
Guidance for the management of ...... tement from a UK Expert Group.
@nl
type
label
Guidance for the management of ...... tement from a UK Expert Group.
@en
Guidance for the management of ...... tement from a UK Expert Group.
@nl
prefLabel
Guidance for the management of ...... tement from a UK Expert Group.
@en
Guidance for the management of ...... tement from a UK Expert Group.
@nl
P2093
P1476
Guidance for the management of ...... atement from a UK Expert Group
@en
P2093
David M Reid
Eugene V McCloskey
Julie Doughty
Peter Selby
Robert E Coleman
Steven D Heys
Trevor Powles
P356
10.1016/J.CTRV.2008.03.007
P478
34 Suppl 1
P577
2008-06-02T00:00:00Z